Catalyst
Slingshot members are tracking this event:
FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADXS |
|
|
||||
Additional Information
“Collaborative discussions with the FDA led to a positive outcome with a SPA that clearly defines the clinical and regulatory pathway for the approval and commercialization of AXAL for the treatment of patients with HRLACC,” said Daniel J. O’Connor, President and Chief Executive Officer. “Obtaining a SPA for the AIM2CERV Phase 3 protocol was our number one priority this year and it has now been achieved.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 06, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cervical Cancer, Axal, Phase 3 Aim2cerv Trial, Lm Immunotherapy Candidate, Axalimogene Filolisbac, Aim2cerv, Listeria Monocytogenes
